Glucagon-like peptide-1 (GLP-1) agonists belong to pharmacological use that helps to treat Type 2 Diabetes Mellitus (T2DM) and in some cases, support the weight loss journey among overweight adults
According to a 2026 paper, faster is not always better
- Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation)
Microdosing GLP-1 is the use of very small, gradual doses of compounded injectable semaglutide or tirzepatide
However, the bodys naturally produced GLP-1 has a very short half-life, lasting only a few minutes before it is rapidly broken down by an enzyme called dipeptidyl peptidase-4 (DPP-4)
Most experts recommend taking them indefinitely, the same way people do blood pressure medication